This clinical study is about testing KITE-363 and KITE-753 drugs on people with a type of cancer called B-cell lymphoma. B-cell lymphoma is when certain blood cells called B-cells grow too much. The study aims to see how safe these drugs are and the right amount to give. People who join the study and receive KITE-363 or KITE-753 will continue in another study for up to 15 years to check on them.
Key points:
- This study is for people whose B-cell lymphoma has returned or not responded to previous treatments.
- Participants need to visit the study site for drug administration and follow-up visits.
- Potential risks include typical side effects of cancer treatments, and eligibility depends on your health history.
There are rules for joining the study. People can join if they have relapsed or refractory B-cell lymphoma and at least one tumor that can be measured. They must also have healthy organs and bone marrow. However, people with other serious health problems, certain infections, or recent cancer treatments may not be able to join.
How understandable was the trial content above?
Hard to understand
Easy to understand